Passage BIO, Inc. 2026: Revenue ($7.82M), Net income ($7.82M), EPS ($2.44) — 10-Q SummaryTradingView·Aug 10 at 06:21 AMPASG-1.09%
13:41 ET$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger--CRNX, SLP, NCSM, and PASGprnewswire·Jul 23 at 12:41 PMPASG-1.09%SLP+0.05%
Lynx1 Capital Management Discloses Investment at Passage BIO with 21.0% StakeTradingView·Jul 2 at 08:26 PMPASG-1.09%
Lynx1 Capital Management LP buys $206,064 of Passage Bio common sharesPUBT·Jun 29 at 03:31 PMPASG-1.09%
12 Health Care Stocks Moving In Thursday's Intraday Sessionbenzinga_article·Jun 25 at 12:05 PMNNOX-6.42%ATLN0.00%
12 Health Care Stocks Moving In Thursday's Pre-Market Sessionbenzinga_article·Jun 25 at 07:05 AMTELA+0.88%PASG-1.09%
9 Health Care Stocks Moving In Wednesday's After-Market Sessionbenzinga_article·Jun 24 at 04:05 PMSPRY+10.44%TSHA+4.37%
Passage Bio shares are trading higher after the company announced it entered into a definitive merger agreement with Remix Therapeutics.benzinga_article·Jun 24 at 03:43 PMPASG-1.09%
Passage Bio agrees to merge with Remix Therapeutics in all-stock dealPUBT·Jun 24 at 03:06 PMPASG-1.09%
This Mohawk Industries Analyst Is No Longer Bullish; Here Are Top 2 Downgrades For Tuesdaybenzinga_article·Apr 21 at 09:30 AMPASG-1.09%MHK-3.40%
Buy Rating Reaffirmed on Encouraging upliFT-D Biomarker Data and Solid Cash Runway Supporting Expanded FTD-GRN TrialTip Ranks·Apr 21 at 06:45 AMPASG-1.09%XBI+1.35%
